Literature DB >> 15546603

Impairment in Guillain-Barré syndrome during the first 2 years after onset: a prospective study.

Anette Forsberg1, Rayomand Press, Ulrika Einarsson, Jésus de Pedro-Cuesta, Lotta Widén Holmqvist.   

Abstract

OBJECTIVES: To provide a comprehensive description of impairment in patients with Guillain-Barre syndrome (GBS) in Sweden during the first 2 years after disease onset.
METHODS: In this prospective multi-centre study, 42 patients, mean age 52 years, were evaluated at 2 weeks, 2 months, 6 months, 1 year and 2 years. Evaluations made use of validated, reliable measures of muscle strength, grip strength, finger dexterity, balance, facial-muscle function, respiratory function, gait, motor performance and sensory examination, and included patients' own assessments of pain, fatigue and paraesthesia.
RESULTS: Mechanical ventilation was required in 21% of patients. At 2 weeks, 1 year and 2 years after GBS onset: 100%, 62% and 55% of patients had submaximal overall muscle strength; 98%, 38% and 31% subnormal grip strength; and 38%, 14% and 12% affected facial-muscle function. At the same time points, 62%, 10% and 7% of patients were unable to walk 10 m independently; and affected sensation was detected in 93%, 55% and 52%.
CONCLUSIONS: Recovery occurred mainly during the first year after onset. At 2 years, motor impairment and sensory impairment were each still detectable in more than 50% of patients. We conclude that residual impairment is significant, somatically widespread and, likely, persistent.

Entities:  

Mesh:

Year:  2004        PMID: 15546603     DOI: 10.1016/j.jns.2004.09.021

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  12 in total

1.  Anatomical changes in the emerging adult brain: a voxel-based morphometry study.

Authors:  Craig M Bennett; Abigail A Baird
Journal:  Hum Brain Mapp       Date:  2006-09       Impact factor: 5.038

Review 2.  Pharmacological treatment for pain in Guillain-Barré syndrome.

Authors:  Jia Liu; Lu-Ning Wang; Ewan D McNicol
Journal:  Cochrane Database Syst Rev       Date:  2015-04-09

Review 3.  Headache and Pain in Guillain-Barré Syndrome.

Authors:  Constantine Farmakidis; Seniha Inan; Mark Milstein; Steven Herskovitz
Journal:  Curr Pain Headache Rep       Date:  2015-08

Review 4.  Fatigue in neuromuscular disorders: focus on Guillain-Barré syndrome and Pompe disease.

Authors:  J M de Vries; M L C Hagemans; J B J Bussmann; A T van der Ploeg; P A van Doorn
Journal:  Cell Mol Life Sci       Date:  2010-03       Impact factor: 9.261

5.  Fatigue, pain and muscle weakness are frequent after Guillain-Barré syndrome and poliomyelitis.

Authors:  Tiina Rekand; Arne Gramstad; Christian A Vedeler
Journal:  J Neurol       Date:  2009-03-06       Impact factor: 4.849

6.  Observer blind randomised controlled trial of a tailored home exercise programme versus usual care in people with stable inflammatory immune mediated neuropathy.

Authors:  Claire M White; Robert D Hadden; Sarah F Robert-Lewis; Paul R McCrone; Jane L Petty
Journal:  BMC Neurol       Date:  2015-08-21       Impact factor: 2.474

7.  Clinical Features of Post-Vaccination Guillain-Barré Syndrome (GBS) in Korea.

Authors:  Yong Shik Park; Keon Joo Lee; Seung Woo Kim; Kyung Min Kim; Bum Chun Suh
Journal:  J Korean Med Sci       Date:  2017-07       Impact factor: 2.153

8.  Respiratory Involvement in Guillain-Barre Syndrome: The Uncharted Road to Recovery.

Authors:  Meenal Garg
Journal:  J Neurosci Rural Pract       Date:  2017 Jul-Sep

9.  Determination of pain and response to methylprednisolone in Guillain-Barré syndrome.

Authors:  Liselotte Ruts; Rinske van Koningsveld; Bart C Jacobs; Pieter A van Doorn
Journal:  J Neurol       Date:  2007-04-11       Impact factor: 4.849

10.  Mitochondrial damage and "plugging" of transport selectively in myelinated, small-diameter axons are major early events in peripheral neuroinflammation.

Authors:  Marija Sajic; Keila Kazue Ida; Ryan Canning; Norman A Gregson; Michael R Duchen; Kenneth J Smith
Journal:  J Neuroinflammation       Date:  2018-02-27       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.